Cumulative dose of chemotherapy and survival outcomes in children with average risk medulloblastoma treated on Children’s Oncology Group study ACNS0331

Puntos clave

• To investigate the relationship between cumulative chemotherapy dose and survival outcomes in children with average risk medulloblastoma.
• Analyzed survival outcomes in children treated under the Children’s Oncology Group study ACNS0331
• Examined dose reductions of vincristine and cisplatin
• Focused on average risk medulloblastoma cases
• Moderate dose reductions (≥25%) in vincristine and cisplatin did not significantly impact survival outcomes
• Larger dose reductions (>50%) were not evaluated in the study